References
tumor
TUMOR, RESIDUAL TUMOR, BRAIN, TUMOR PROGRESSION, CAVITY
A comparison between the ratio map of choline to N-acetylaspartate (Cho/NAA) and T1-weighted contrast-enhanced (T1w-CE) imaging for three patients on the trial. For each patient, the top left image contains the Cho/NAA ratio map superimposed on the T1w image along with a contour encompassing all voxels with a Cho/NAA ≥ 2x normal. That contour is overlaid on the T1w-CE image on the top right image which shows enhancement from residual tumor and recent surgery. The bottom left image shows a 3D volume rendering of the volume of tissue that received 75 Gy of radiation guided by the Cho/NAA ≥ 2x contour, while the bottom right image shows a 3D volume rendering of the residual contrast enhancing lesion, which normally receives 60 Gy of radiation along with resection cavity in standard therapies. In all cases, the Cho/NAA ≥ 2x contour was significantly larger than the contrast-enhancing lesion.A view of the Brain Imaging Collaboration Suite Longitudinal Imaging Tracker (BrICS-LIT). The top row consists of T2-weighted fluid-attenuated inversion recovery (FLAIR) MRIs and the middle row of T1w-CE MRIs co-registered and interpolated to an atlas for easier comparison. Studies are longitudinally arranged from newest (left column) to oldest (right column). Segmented lesions are overlaid in the top two rows, while the radiation dose map is overlaid on the T1w-CE MRI in the bottom row to intuitively determine the radiation dose received of the suspected recurring tumor.Kaplan–Meier estimator for PFS; median PFS: 16.6 months with a median time to follow-up of 20.3 months.With our web platform, clinicians assessed ((Compiled genetic and PFS data for 14 of the 19 patients with confirmed tumor progression.